CagriSema 10mg (Blend) yu gi oh.

▎ Wetin na Semaglutid?

Semaglutid, as wan lכng-aktin glukagon lεk pεptida-1 (GLP-1) rεsεptכr agonist, dεn bin yus am bכku bכku wan insay di klinik tritmεnt fכ tayp 2 dayabεtis mεlitus. bay we i de miks di fisiolכjik fכnshכn dεm fכ nεchכral GLP-1, dis dכg de trigεr mכltipכl mεtabolik rεguleshכn mεkanism dεm afta i aktibכt di GLP-1 rεsεpכta, inklud di εnhansmεnt fכ glukכs-dipεndεnt insulin sekreshכn, di inhibitory rεguleshכn fכ glukכn rilis, di dilay fכ gastric εmpti rεt, εn di sεntri apεtit sכpreshכn ifekt, we de achy di sinagεstik ifekt fכ prεsis kכntrכl fכ blכd glukכs di lεvεl dεm εn di wet mεnejmεnt. I yunik famakokinɛtik prɔpati dɛn de gi am af-layf we go rich 7 dez, we de sɔpɔt wan tɛm insay di wik sabkyutan injɛkshɔn rijim ɔ wan de ɔral administreshɔn mɔd, we rili ɔptimayz di tritmɛnt ɛkspiriɛns fɔ di pasɛnt dɛn ɛn impruv di mɛrɛsin kɔmplians.

di klinik trial data sho se semaglutide kin ridyus di lεvεl fכ glycated hemoglobin (HbA1c) bכku bכku wan bay 1.8%, εn di insidεns fכ haypoglycemic ivent dεm rili lכw, we de gi am wan yכnik advantej fכ mεnejmεnt fכ blכd glukכs. Apat frɔm dat, dɛn dɔn fulɔp fɔ chɛk di kadyovaskyuɛl prɔtɛktiv ifɛkt fɔ dis drɔg, we kin ridyus di risk fɔ big bad bad tin dɛn we kin apin to di at ɛn di blɔd bay 26%, we kin gi ɔda tritmɛnt bɛnifit fɔ di wan dɛn we gɛt dayabitis we gɛt sik dɛn we de ambɔg di at ɛn di blɔd. Apat frɔm di tritmɛnt fɔ dayabitis, dɛn kin yuz semaglutide fɔ di lɔng tɛm mɛnejɛmɛnt fɔ fat ɛn i dɔn sho se i kin gɛt pɔtnɛshɛl tritmɛnt valyu pan klinik risach pan sik dɛm lɛk nɔ-alkohol stiatohepatitis ɛn Alzaima sik.

dis mכlti-targεt tritmεnt mεkanism we bεys pan GLP-1 rεsεptכr aktibכshכn nכto כnli kכmprεhεnsiv כptimayz mεtabolik paramita dεm bay we i de impruv insulin sεnsitiviti, inhεbit εksyכs glukagon sekreshכn, εn rεgul di sεntri εnεji bεlε sεnta, bכt i de gi wan nyu tritmεnt stratεji fכ di kכmprεhεnsiv mεnejmεnt fכ krכnik mεtabolik sik dεm tru di kכdivaskyul protεktiv ifekt εn pכtεnshal bεnεfit dεm fכ di sεntri nεv sistεm. i aplikeshכn pכtεnshal in mכltipכl sik εria dεm de kכnfכm di imכtant posishכn fכ GLP-1 rεsεptכr agonist dεm as kכr tritmεnt mεtכd in mכdan mεtabolik mεdisin.

▎ Sɔmari

Di kɔmbaynshɔn fɔ Cagrilintide ɛn Semaglutid (Cagrisema) sho signifyant sinajɛstik ifɛkt dɛn na di tritmɛnt fɔ fat ɛn tayp 2 dayabitis mɛlitus. dis kכmbaynshכn tεrapi de achy mכlti-dimεnshכnal rεguleshכn fכ apεtit, bכdi glukכs mεtabolism, εn weit mεnejmεnt bay we i de tכk to di amylin εn GLP-1 rεsεpכta dεm wan tεm. di kagrilintayd de rεgεl tru dilay gεstrik εmpti εn sεntri satiety rεgulεshכn, we Semaglutid de inhεbit glukagon sekreshכn εn i de εnhans insulin sekreshכn. di sinagεstik ifekt fכ di tu de sכmtεm εnhans di ifekt dεm we di wet lכs εn blכd glukכs kכntrכl.

Klinik trayal data sho se Cagrisema (di kɔmbaynshɔn fɔ Cagrilintide 2.4mg ɛn Semaglutid 2.4mg) de mek pɔsin lɔs avɛrej wet we na 9.07% (wan absɔlɔb wet lɔs we na 9.11kg) insay di tritmɛnt tɛm we na 20 to 32 wik, we rili bɛtɛ pas di tritmɛnt we dɛn yuz Semaglutid 2.4mg wan tɛm insay di wik in wan ^[1] . Insay wan 32 wik, multicenter, double-blind, phase 2 klinik trial, di weit we di pasɛnt dɛn we dɛn trit wit CagriSema bin lɔs bin rili big pas di wan dɛn we dɛn trit wit Semaglutid ɔ Cagrilintide nɔmɔ. 

di wet lכs na di CagriSema grup na bin -15.6%, dat na di Semaglutid grup na -5.1%, εn di wan na di Cagrilintide grup na -8.1% ^[2] . pan tap dat, Cagrisema de du fayn bak fכ ridyus glycated hemoglobin (HbA1c) εn impruv di kכdivaskyul risk indikεtכ dεm, we di risk fכ haypoglycemia rili lכw. Tru wan mכlti-target mεkanism, dis kכmbayn tritmεnt rεjim nכ de כnli optimiz mεtabolik paramita dεm bכt i de ridyus di risk fכ kכdivaskyul ivent dεm bכku bכku wan, we de gi mכr kכmprεhεnsiv tritmεnt opshכn fכ pasεn dεm we fat εn tayp 2 dayabεtis mεlitus.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

▎Sayteshɔn dɛn we gɛt fɔ du wit dis

[1] Dutta D, Nagendra L, Harish B. G., ɛn ɔda pipul dɛn. Efikεsi εn Sefty כf Cagrilintide nכmכ εn in Kכmbayn wit Semaglutid (Cagrisema) as Anti-Obesity Mεdikeshכn: Wan Sistεmatik Rivyu εn Mεta-Analysis[J]. Indian Jɔnal fɔ Ɛndokrinɔlɔji ɛn Mɛtabolism, 2024,28:436-444.DOI:10.4103/ijem.ijem_45_24.

[2] Frias JP, Deenadayalan S, Erichsen L, ɛn ɔda pipul dɛn. Efikεsi εn sef fכ kכ-administret wan tεm insay wik kagrilintayd 2·4 mg wit wan tεm insay wik semaglutide 2·4 mg insay tayp 2 dayabεtis: wan mכltisεntr, randomizεd, dכbl-blaynd, aktv-kכntrol, fεz 2 trayal[J]. Lancet, 2023,402(10403):720-730.DOI:10.1016/S0140-6736(23)01163-7.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.